We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





NEXTGENPCR Endpoint Thermocycler Decreases PCR Amplification Time for SARS-CoV-2 to Eight Minutes

By LabMedica International staff writers
Posted on 06 Apr 2020
Molecular Biology Systems, B.V. More...
(Goes, The Netherlands), a biotechnology company, has developed a method using its NEXTGENPCR endpoint thermocycler and consumables that decreases PCR amplification time for SARS-CoV-2 to eight minutes. Combined with smaller reaction volumes, increased samples per run, and standard, affordable laboratory equipment, a qualitative protocol was generated that could readily detect SARS-CoV-2 control DNA, with equivalent sensitivity. A single unit, the size of a shoebox, could perform a hundred and eighty (180) amplification runs a day, an almost 10-fold increase over the current US Centers for Disease Control (CDC) recommended instrumentation. The detection of amplified product can be done with widely-available blue light gel document systems.

The NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results. Since the NEXTGENPCR accepts both 96 and 384-well reaction plates, the company tested both versions to increase throughput. By utilizing 384-well plates, the machine successfully processed four times as many samples without a loss in performance. The 384-well reaction chambers only require 25% of the reaction volume which would lower the supply burden placed on laboratories following the current CDC protocol. The company is now collaborating with testing laboratories in the US and the Netherlands to transfer and validate the method.

“We sought to decrease what we identified as the longest step in the current testing scheme, amplification. We started with the CDC assay because it is well characterized and has been readily available,” said Gert de Vos, CEO and founder of Molecular Biology Systems. “This protocol produces a simple yes/no answer — so a single machine, is capable of running 24/7, with eight-minute runs may provide a scalable screening solution analyzing 22,860 samples per day.”

Related Links:
Molecular Biology Systems, B.V.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
New
Gastrointestinal Panel
Xpert® GI Panel
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

New Insights Into Fetal DNA Could Improve Non-Invasive Prenatal Testing

Non-invasive prenatal testing is widely used to screen pregnancies for genetic conditions by analyzing DNA fragments in maternal blood. Although it offers a safer alternative to invasive procedures such... Read more

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.